SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-204214
Filing Date
2018-06-26
Accepted
2018-06-26 17:18:35
Documents
7
Period of Report
2018-06-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d820307d8k.htm 8-K 21361
2 EX-10.1 d820307dex101.htm EX-10.1 75614
3 EX-10.2 d820307dex102.htm EX-10.2 83451
4 EX-99.1 d820307dex991.htm EX-99.1 11503
5 GRAPHIC g820307dsp14.jpg GRAPHIC 273840
6 GRAPHIC g820307g0626045502802.jpg GRAPHIC 4933
7 GRAPHIC g820307page7.jpg GRAPHIC 66712
  Complete submission text file 0001193125-18-204214.txt   669385
Mailing Address 950 WINTER STREET WALTHAM MA 02451
Business Address 950 WINTER STREET WALTHAM MA 02451 (858) 909-0749
Eloxx Pharmaceuticals, Inc. (Filer) CIK: 0001035354 (see all company filings)

IRS No.: 841368850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31326 | Film No.: 18920060
SIC: 8731 Services-Commercial Physical & Biological Research
Office of Trade & Services